74 related articles for article (PubMed ID: 19125382)
1. Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.
Palandri F; Testoni N; Luatti S; Marzocchi G; Baldazzi C; Stacchini M; Castagnetti F; Breccia M; Specchia G; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G
Leuk Lymphoma; 2009 Jan; 50(1):114-8. PubMed ID: 19125382
[No Abstract] [Full Text] [Related]
2. Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.
Cannella L; Loglisci G; Nanni M; De Cuia MR; Colafigli G; Salaroli A; Serrao A; Alimena G; Breccia M
Leuk Lymphoma; 2012 Mar; 53(3):497-8. PubMed ID: 21854086
[No Abstract] [Full Text] [Related]
3. [The prognostic implications of secondary chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia patients after imatinib mesylate treatment].
Zhang Y; Jiang Q; Qiu JY; Chen SS; Jiang B; Huang XJ
Zhonghua Nei Ke Za Zhi; 2007 Aug; 46(8):648-50. PubMed ID: 17967235
[TBL] [Abstract][Full Text] [Related]
4. Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia.
Fava C; Cortes J
Am J Hematol; 2008 Sep; 83(9):755. PubMed ID: 18615551
[No Abstract] [Full Text] [Related]
5. First-line treatment with imatinib mesylate in patients with chronic phase chronic myeloid leukemia: experience of a public hospital in a developing country of South America.
da Silveira CA; Ferrari I
Leuk Lymphoma; 2012 Jul; 53(7):1417-9. PubMed ID: 22204455
[No Abstract] [Full Text] [Related]
6. Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia.
Cortes JE
J Clin Oncol; 2012 Jan; 30(3):223-4. PubMed ID: 22184376
[No Abstract] [Full Text] [Related]
7. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
Cervantes F; López-Garrido P; Montero MI; Jonte F; Martínez J; Hernández-Boluda JC; Calbacho M; Sureda A; Pérez-Rus G; Nieto JB; Pérez-López C; Román-Gómez J; González M; Pereira A; Colomer D
Haematologica; 2010 Aug; 95(8):1317-24. PubMed ID: 20220063
[TBL] [Abstract][Full Text] [Related]
8. Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia.
Ross DM; Jackson SR; Browett PJ
Leuk Lymphoma; 2007 Jun; 48(6):1231-3. PubMed ID: 17577792
[No Abstract] [Full Text] [Related]
9. Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country.
Aziz Z; Iqbal J; Bano K; Faisal M; Akram M
Jpn J Clin Oncol; 2010 Jun; 40(6):549-55. PubMed ID: 20189974
[TBL] [Abstract][Full Text] [Related]
10. Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer?
DeAngelo DJ; Ritz J
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):1-3. PubMed ID: 14734443
[No Abstract] [Full Text] [Related]
11. Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment.
Royer-Pokora B; Hildebrandt B; Redmann A; Herold C; Kronenwett R; Haas R; Drechsler M; Wieland C
Leukemia; 2003 Apr; 17(4):807-10. PubMed ID: 12682644
[No Abstract] [Full Text] [Related]
12. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Medina J; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Rios MB; Hayes K; Cortes J
Cancer; 2003 Nov; 98(9):1905-11. PubMed ID: 14584073
[TBL] [Abstract][Full Text] [Related]
13. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M
J Clin Oncol; 2005 Jun; 23(18):4100-9. PubMed ID: 15867198
[TBL] [Abstract][Full Text] [Related]
14. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
15. [A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up].
Hołowiecki J; Konopka L; Bober G; Giebel S; Ceglarek B; Kos K; Stella-Hołowiecka B; Kruzel T; Kopera M; Bartkowska-Chrobok A; Pszenna E; Sikorska A; Pieńikowska-Grela B
Pol Arch Med Wewn; 2006 Jun; 115(6):535-44. PubMed ID: 17263225
[TBL] [Abstract][Full Text] [Related]
16. Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.
Breccia M; Latagliata R; Molica M; Colafigli G; Mancini M; Diverio D; Tafuri A; Alimena G
Am J Hematol; 2015 May; 90(5):E95-6. PubMed ID: 25683237
[No Abstract] [Full Text] [Related]
17. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.
Sohn SK; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Yoon SS; Kim H; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Moon JH; Park SY
Leuk Lymphoma; 2011 Jun; 52(6):1024-9. PubMed ID: 21463107
[TBL] [Abstract][Full Text] [Related]
18. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.
Luatti S; Castagnetti F; Marzocchi G; Baldazzi C; Gugliotta G; Iacobucci I; Specchia G; Zanatta L; Rege-Cambrin G; Mancini M; Abruzzese E; Zaccaria A; Grimoldi MG; Gozzetti A; Ameli G; Capucci MA; Palka G; Bernasconi P; Palandri F; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M; Testoni N;
Blood; 2012 Jul; 120(4):761-7. PubMed ID: 22692507
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
Breccia M; Cannella L; Stefanizzi C; Latagliata R; Nanni M; Diverio D; Santopietro M; Federico V; Alimena G
Hematol Oncol; 2010 Jun; 28(2):89-92. PubMed ID: 19728398
[TBL] [Abstract][Full Text] [Related]
20. The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate.
Lee SE; Choi SY; Bang JH; Kim SH; Jang EJ; Byeun JY; Park JE; Jeon HR; Oh YJ; Kim M; Kim DW
Cancer Genet; 2012 Nov; 205(11):563-71. PubMed ID: 23111092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
